PRF Technologies Ltd. (PRFX)

Market Cap	1.29M -60.9%
Revenue (ttm)	17,000
Net Income	-4.84M
EPS	-7.47
Shares Out	868.76K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,357
Open	1.370
Previous Close	1.450
Day's Range	1.340 - 1.530
52-Week Range	1.280 - 17.950
Beta	0.77
Analysts	Hold
Price Target	240.00 (+16,007.38%)
Earnings Date	Mar 26, 2026

About PRFX

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 1, 2020
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: PRFX
• Website: https://www.painreform.com

Analyst Summary

According to one analyst, the rating for PRFX stock is "Hold" and the 12-month stock price target is $240.0.

Price Target

$240.0

(16,007.38% upside)

Analyst Consensus: Hold